Share Twitter LinkedIn Facebook Email Dr. John Kisiel, MD, Mayo Clinic, talks Setting Specificity and Sensitivity for Tests | Involves recruiting up to 500 At-Risk Control Patients for DDW 2018
FDA Approves Keytruda / Pembrolizumab for HER2-Positive Gastric Cancer: A Potential New Hope for Patients Gastrointestinal 3 Mins Read
FDA Approves TEVIMBRA for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma Gastrointestinal 3 Mins Read
Why isn’t CAR-T Therapy Revolutionizing the Fight Against GI Cancers? 17 Trial Insights from ASCO GI 2025 Gastrointestinal 4 Mins Read